BRIEF

on VALBIOTIS (EPA:ALVAL)

Valbiotis Terminate Licensing Agreement with Nestlé Health Science

Valbiotis has announced the termination of its licensing and supply agreement with Nestlé Health Science. This strategic shift allows Valbiotis to regain full intellectual property rights for TOTUM•63, a plant-based supplement targeting prediabetes and early stages of type 2 diabetes.

This decision follows Nestlé Health Science's refocused priorities in the health nutrition market. The agreement, effective May 31, 2024, transfers all patents and clinical data of TOTUM•63 to Valbiotis, including rights across 62 countries. No reimbursement of the 12.75 million Swiss francs provided by Nestlé Health Science is required.

With a cash position of €25 million as of December 2023, Valbiotis plans the direct launch of TOTUM•63 in France by early 2025 and seeks new international partnerships. The company continues to advance its other dietary supplements, TOTUM•854 and TOTUM•448, maintaining its strategic priorities.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news